Goldman Sachs Group Inc. reissued their buy rating on shares of Bluebird Bio Inc. (NASDAQ:BLUE) in a report released on Saturday morning. Goldman Sachs Group Inc. currently has a $135.00 price objective on the stock.
Several other equities analysts have also commented on BLUE. Vetr raised shares of Bluebird Bio from a buy rating to a strong-buy rating and set a $44.44 price target for the company in a research report on Monday, June 27th. BTIG Research reaffirmed a buy rating and set a $72.00 price target on shares of Bluebird Bio in a research report on Wednesday, June 29th. Jefferies Group reaffirmed a buy rating and set a $80.00 price target on shares of Bluebird Bio in a research report on Friday, July 8th. Wedbush reaffirmed an outperform rating and set a $117.00 price target on shares of Bluebird Bio in a research report on Wednesday, August 3rd. Finally, Maxim Group reaffirmed a buy rating and set a $85.00 price target (down previously from $105.00) on shares of Bluebird Bio in a research report on Thursday, August 4th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and fourteen have assigned a buy rating to the company. Bluebird Bio has an average rating of Buy and a consensus price target of $91.60.
Shares of Bluebird Bio (NASDAQ:BLUE) traded down 13.29% during midday trading on Friday, reaching $56.57. 4,144,106 shares of the company traded hands. The company has a 50 day moving average of $63.71 and a 200 day moving average of $50.93. The firm’s market capitalization is $2.10 billion. Bluebird Bio has a 12 month low of $35.37 and a 12 month high of $99.70.
Bluebird Bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported ($1.59) EPS for the quarter, missing the consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The company had revenue of $1.55 million for the quarter, compared to analyst estimates of $2.01 million. During the same period last year, the company posted ($1.57) EPS. The business’s revenue for the quarter was down 68.6% on a year-over-year basis. On average, equities research analysts predict that Bluebird Bio will post ($6.19) earnings per share for the current fiscal year.
In other Bluebird Bio news, insider Eric Sullivan sold 2,912 shares of the stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $55.01, for a total transaction of $160,189.12. Following the sale, the insider now directly owns 4,456 shares of the company’s stock, valued at $245,124.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.50% of the stock is currently owned by corporate insiders.
Several hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new stake in shares of Bluebird Bio during the first quarter worth $1,641,000. Wellington Management Group LLP acquired a new stake in shares of Bluebird Bio during the first quarter worth $51,095,000. Tiverton Asset Management LLC acquired a new stake in shares of Bluebird Bio during the first quarter worth $3,957,000. AXA boosted its stake in shares of Bluebird Bio by 19.3% in the first quarter. AXA now owns 148,851 shares of the company’s stock worth $6,326,000 after buying an additional 24,053 shares during the period. Finally, UBS Asset Management Americas Inc. boosted its stake in shares of Bluebird Bio by 0.8% in the first quarter. UBS Asset Management Americas Inc. now owns 157,666 shares of the company’s stock worth $6,701,000 after buying an additional 1,194 shares during the period.
Bluebird Bio Company Profile
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.